Article Detail

Home > Article Detail
  • P-ISSN 1225-0163
  • E-ISSN 2288-8985

Determination of the quantity of tolperisone hydrochloride in tablets by high performance liquid chromatography

Analytical Science and Technology / Analytical Science and Technology, (P)1225-0163; (E)2288-8985
2017, v.30 no.1, pp.32-38
https://doi.org/10.5806/AST.2017.30.1.32
Quoc Ky Truong

Xuan Lan Mai





(The Society of Korean Official Compendium for Publ)
  • Downloaded
  • Viewed

Abstract

In attempt to contribute in official monographs of Korean Pharmacopoeia, an HPLC method was developed and fully validated for the determination of tolperisone hydrochloride in tablets which have never been published in other forgein Pharmacopoeia. Analysis was carried out in an ODS column (250 × 4.6 mm I.D., 5 μm) with common solvents include acetonitrile and ammonium hydrophosphate buffer as mobile phase. The assay was validated according to International Conference on Harmonization (ICH) guidelines. The method has good linearity in the range of 5 – 200 μg/mL tolperisone. Intra-day precision varied between 0.04 and 0.10 %. Relative standard deviations of inter-day precision ranged between 0.43 and 1.24 % for peak area. The percentage recovery of the tolperisone ranged between 99.8 and 101.2 % in material. Recoveries in tablets were ranged between 98.7 and 100.8 %, thus confirmed the suitability of method for estimation of tolperisone hydrochloride in tablet dosage form.

keywords
tolperisone, HPLC, assay, validation, tablet dosage form


Reference

1

1. Martindale, The Extra Pharmacopoeia 30th edition, A. G. Lipman, The Pharmaceutical Press, London, 1211(1993).

2

2. The Japanese Pharmacopoeia, 17th Edition, The Ministry of Health, Labour and Welfare, Japan (2016).

3

3. The Korean Pharmacopoeia, 11th Edition, Ministry of Food and Drug Safety, Republic of Korea (2014).

4

4. N. Youngvises, B. Liawruangrath, and S. Liawruangrath, J. Pharm. Biomed. Anal., 31, 629-638 (2003).

5

5. S. Liawruangrath, B. Liawruangrath, and P. Pibool, J. Pharm. Biomed. Anal., 26, 865-872 (2001).

6

6. N. R. Rao and S. S. Raju, Chirality, 25(10), 622-627(2013).

7

7. I. C. Nimila, P. Balan, N. Chiranjeevi, and V. V. V. M. Kumar, Int. J. Pharm. Pharm. Sci., 4(5), 84-85 (2012).

8

8. N. Miura, T. Saito, T. Taira, T. Yamagiwa, S. Morita, and S. Inokuchi, J. AOAC Int., 97(6), 1546-1551 (2014).

9

9. T. V. R. Raju, R. K. Seshadri, S. Arutla, T. S. S. J. Mohan, I. M. Rao, and S. R. Nittala, Sci. Pharm., 81, 123-138 (2013).

10

10. J. W. Bea, Y. S. Park, U. D. Sohn, C. S. Myung, B. K. Ryu, C. G. Jang, and S. Y. Lee, Arch. Pharm. Res., 29(4), 399-342 (2006).

11

11. C. I. Choi, J. I. Park, H. I. Lee, Y. J. Lee, C. G. Jang, J.W. Bea, and S. Y. Lee, J. Chromatogr. B, 911, 59-63(2012).

12

12. Y. Owada, M. Takahashi, S. Iwasa, H. Ichiba, K. Sadamoto, and T. Fukushima, Biomed. Chromatogr., 28, 102-105(2014).

13

13. M. Murali and P. V. V. Satyanarayana, Der Pharma. Chemica, 3(5), 13-19 (2011).

14

14. ICH Guideline. Q2(R1): validation of Analytical Procedures: Text and Methodology Q2(R1) in ICH Harmonised Tripartite Guideline (2005).

상단으로 이동

Analytical Science and Technology